11 patents
Utility
Nasal Formulations of Foralumab
16 Nov 23
This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages and dosing regimens of anti-CD3 antibodies, as well as to methods for using such formulations and dosages and dosing regimens.
Jules S. JACOB, Vaseem A. PALEJWALA, Kunwar SHAILUBHAI
Filed: 15 May 23
Utility
CD-3 Antibodies for the Treatment of Coronavirus
20 Jul 23
This invention provides methods for treating and preventing symptoms of coronavirus infections using antibodies that recognize CD3.
Kunwar SHAILUBHAI, Howard L. Weiner
Filed: 30 Jul 21
Utility
Subcutaneous Administration of Antibodies for the Treatment of Disease
20 Oct 22
This invention provides methods of subcutaneous administration of anti-CD3 monoclonal antibodies (mAbs) either alone or in combination with monoclonal antibodies, that recognize the Interleukin-6 (IL-6) and IL-6 receptor (IL-6R) complex for the treatment, prevention or alleviating a symptom of a disease.
Kunwar SHAILUBHAI, Vaseem A. PALEJWALA, Jules S. JACOB
Filed: 18 Apr 22
Utility
Composition and Methods of Treating Inflammatory and Autoimmune Diseases
13 Jan 22
This invention relates to methods of treating disorders such as celiac disease by administrating anti-CD3 antibodies alone or in combination with additional agents.
Kunwar SHAILUBHAI
Filed: 31 Oct 19
Utility
Compositions of IL-6/IL-6R Antibodies and Methods of Use Thereof
16 Sep 21
The present disclosure provides compositions and methods for the treatment of coronavirus infections, such as SAR-CoV, SARS-CoV-2, and MERS-CoV.
Kunwar SHAILUBHAI, Gabriele CERRONE, Vaseem A. PALEJWALA, Jules S. JACOB
Filed: 10 Mar 21
Utility
Dactinomycin Compositions and Methods for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia
9 Sep 21
The disclosure provides compositions comprising dactinomycin, formulated for delivery by nanoparticle, and methods for treating a myelodysplastic syndrome (MDS) or cancer, for example, NPM1-mutated acute myeloid leukemia (AML), by administration of the compositions of the disclosure.
Kunwar SHAILUBHAI
Filed: 5 Mar 21
Utility
Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
13 Apr 21
The disclosure provides compositions comprising dactinomycin, formulated for delivery by nanoparticle, and methods for treating a myelodysplastic syndrome (MDS) or cancer, for example, NPM1-mutated acute myeloid leukemia (AML), by administration of the compositions of the disclosure.
Kunwar Shailubhai
Filed: 13 Sep 17
Utility
ANTI-CD3 Antibody Formulations
6 Jan 21
This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages and dosing regimens of anti-CD3 antibodies, as well as to methods for using such formulations and dosages and dosing regimens.
Kunwar SHAILUBHAI
Filed: 17 May 20
Utility
Formulations of Milciclib and Therapeutic Combinations of the Same for Use In the Treatment of Cancer
16 Dec 20
This application relates to methods of treating and/or preventing cancer (e.g., non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma) in patients in need thereof comprising administering to the patient a therapeutically effective amount of a CDK inhibitor (e.g., milciclib) in combination with a therapeutically effective amount of another anticancer drug (e.g., sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib).
Kunwar SHAILUBHAI
Filed: 28 Jun 20
Utility
Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
31 Aug 20
This application relates to methods of treating and/or preventing cancer (e.g., non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma) in patients in need thereof comprising administering to the patient a therapeutically effective amount of a CDK inhibitor (e.g., milciclib) in combination with a therapeutically effective amount of another anticancer drug (e.g., sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib).
Kunwar Shailubhai
Filed: 5 Nov 18
Utility
Anti-CD3 antibody formulations
22 Jun 20
This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages and dosing regimens of anti-CD3 antibodies, as well as to methods for using such formulations and dosages and dosing regimens.
Kunwar Shailubhai
Filed: 28 Aug 17
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first